RESEARCH PAPER
Prevalence of neoplasms in patients with acromegaly – the need for a national registry
 
More details
Hide details
1
Department of Endocrinology, Medical University, Lublin, Poland
2
Department of Epidemiology and Clinical Research Methodology, Medical University, Lublin, Poland
3
Institute of Rural Health, Lublin, Poland
CORRESPONDING AUTHOR
Beata Matyjaszek-Matuszek   

Department of Endocrinology at Medical University, Lublin, Jaczewskiego 8, 20-954 Lublin, Poland
 
Ann Agric Environ Med. 2018;25(3):559–561
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Acromegaly is an endocrine disorder caused predominantly by pituitary adenoma leading to autonomic oversecretion of growth hormone and secondary elevation of insulin-like growth factor 1 (IGF-1). Consequently, there are both theoretical and experimental grounds for establishing a correlation between this disorder and the higher incidence of neoplasms.

Objective:
The aim of the study is to evaluate the incidence and types of neoplasms among patients with acromegaly.

Material and methods:
The study included 67 patients with acromegaly, aged between 24 and 75±18.8 years, 46 women (68.7%) and 21 men (31.3%), BMI: 30.7±5.7 kg/m2, age at diagnosis 49.1±12.5 years, with the medians of GH and IGF-1 levels at diagnosis of 11.3 ng/ml and 663.8 ng/ml, respectively. A retrospective analysis of medical records with particular regard to physical examination, medical history, laboratory and imaging tests was performed.

Results:
Fifty-one patients (76.1%) suffered from at least one neoplasm, among whom 48 patients (71.6%) had benign proliferations, whereas malignant neoplasms (larynx, endometrial and colon cancers) were found in only three patients (4.5%).

 
REFERENCES (23)
1.
Kałużny M, Bolanowski M. Acromegaly-from myths to facts. Endokrynol Pol. 2008 May-Jun; 59(3): 242–4. PMID:18615400.
 
2.
Zgliczyński W. Postępy w rozpoznawaniu i leczeniu akromegalii. Postępy Nauk Medycznych. 2008; 2: 64–8.
 
3.
Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999; 2: 29–41. doi:10.1023/A:1009965803750.
 
4.
Rocznik Demograficzny GUS. Zakład Wydawnictw Statystycznych. Warszawa, 2016, 30 (in Polish).
 
5.
Orme SM, McNally RJQ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998, 83: 2730–4. doi:10.1210/jcem.83.8.5007.
 
6.
Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrine Rev. 2004; 25: 102–152. doi:10.1210/er2002-0022.
 
7.
Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008; 22(4): 639–57. doi: 10.1016/j.beem.2008.08.011.
 
8.
Jenkins PJ, Mukherjeet A, Shalett SM. Does growth hormone cause cancer? Clin Endocrinol. 2006; 64: 115–21. PMID: 16430706 doi:10.1111/j.1365-2265.2005.02404.x.
 
9.
Chabra Y, Waters MJ, Brooks AJ. Role of the growth hormone-IGF-1axis in cancer. Expert Rev Endocrinol Metabolism. 2011; 6(1): 71–84. doi:10.1586/eem.10.73.
 
10.
Tornell J, Carlsson B, Pohjanen P, et al. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Molec Biol. 1992; 43: 237–42. PMID: 1525063.
 
11.
Bates P, Fisher R, Ward A, et al. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). British J Cancer. 1995; 72: 1189–93. PMID: 7577466 PMCID: PMC2033962.
 
12.
Yang XF, Beamer WG, Huynh H, et al. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. 1996; 56: 1509–11. PMID:8603394.
 
13.
Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003; 63: 4384–8. PMID: 12907608.
 
14.
Bałdys-Waligórska A, Krzentowska A, Gołkowski F, et al. The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol. 2010; 61(1): 29–34. PMID:20205101.
 
15.
Bolanowski M, Ruchała M, Zgliczyński W, et al. Acromegaly-a novel view of the patient. Polish proposal for diagnostic and therapeutic procedure in the light of recent reports. Endokrynol Pol. 2014; 65(4): 326–31. doi:10.5603/EP.2014.0045.
 
16.
Kurimoto M, Fukuda I, Hizuka N, et al. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 2008; 55(1): 67–71. PMID:18202526.
 
17.
Lesen E, Granfeldt D, Houchard A, et al. Comorbidities and treatment patterns among patients with acromegaly in Sweden: a register-linkage population-based study. Endocrine Abstracts. 2016, 41: EP873 doi:10.1530/endoabs.41.EP873.
 
18.
Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008; 14: 3484–9. PMID: 18567075 PMCID: PMC2716609.
 
19.
Woliński K, Czarnywojtek A, Ruchała M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly: a Meta -analysis and systemic review. PLoS One. 2014 Feb 14; 9(2) doi:10.1371/journal.pone.0088787.
 
20.
Nabarro JDN. Acromegaly. Clin Endocrinol. (Oxf). 1987 Apr; 26(4): 481–512. PMID:3308190.
 
21.
Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab. 2001; 86: 2929–34. PMID: 11443145 doi:10.1210/jcem.86.7.7635.
 
22.
Petroff D, Tönjes A, Grussendorf M, et al. The Incidence of Cancer Among Acromegaly Patients: Results from the German Acromegaly Registry. J Clin Endocrinol Metab. 2015 Oct; 100(10): 3894–902. doi:10.1210/jc.2015-2372.
 
23.
Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002; 13: 395. doi:10.1023/A:1015713732717.
 
eISSN:1898-2263
ISSN:1232-1966